All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 10th October 2017, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to gilteritinib, a Fms Like Tyrosine Kinase 3 (FLT3) inhibitor, for the treatment of adult patients with FLT3 mutation positive (FLT3+) Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML).1 This comes after the recent Orphan Drug Designation for gilteritinib granted by the FDA in July 2017.
Gilteritinib is a potent, oral FLT3/AXL inhibitor, which binds to and inhibits both the wild-type and mutated forms of FLT3. Data from a phase I/II dose escalation study (NCT02421939), which was published in Lancet Oncology (as reported by the AGP) revealed that gilteritinib monotherapy was well tolerated and generated frequent, prolonged, clinically important responses in FLT3 mutated patients with R/R AML.2 Additionally in an interview with the AGP, Alexander E. Perl from the Abramson Comprehensive Cancer Center, University of Pennsylvania said that gilteritinib showed “limited efficacy in patients that did not have FLT3 mutations suggesting that this agent is highly selective in its activity against the FLT3 inhibition”.
Presently, gilteritinib is being explored in multiple studies including the phase III ADMIRAL study (NCT02421939), which is assessing oral gilteritinib 120 mg/day in R/R AML patients with FLT3 mutations after first-line therapy.
Subscribe to get the best content related to AML delivered to your inbox